The purpose of this study is to measure cardiovascular outcomes with orforglipron compared with placebo in participants with atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). Participation in the study will last about 5 years.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Time to First Occurrence of Composite Endpoint of Major Cardiovascular Events
Timeframe: Baseline up to end of study (about 5 years)
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or